VERSATOPE THERAPEUTICS INC

LOWELL, MASSACHUSETTS 018524574

$9.46M
Total Contract Value
20 awards
First Award
May 6, 2022
Last Award
May 29, 2025
Business Size
small
CAGE Code
7TEE7

Top Industries (NAICS)

NAICS CodeObligationsAwards
541714$9.46M19

Contract Awards

11 awards found

75N93019C00060
Department of Health and Human Services
$955K
May 29, 2025

DEVELOPMENT OF MEDICAL COUNTERMEASURES FOR BIOTHREAT AGENTS, ANTIMICROBIAL-RESISTANT INFECTIONS AND EMERGING INFECTIOUS DISEASES.

NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2025
75N93019C00060
Department of Health and Human Services
$1.69M
Jul 28, 2024

TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS.

NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2024
75N93019C00060
Department of Health and Human Services
$384K
Jun 12, 2024

TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS.

NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2024
75N93019C00060
Department of Health and Human Services
$1.05M
May 28, 2024

TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS.

NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2024
75N93019C00060
Department of Health and Human Services
$481K
May 1, 2024

TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS.

NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2024
75N93019C00060
Department of Health and Human Services
$597K
Sep 13, 2023

TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS.

NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2023
75N93019C00060
Department of Health and Human Services
$2.49M
Aug 30, 2023

TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS.

NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2023
75N93019C00060
Department of Health and Human Services
$701K
Apr 12, 2023

TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS.

NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2023
75N93019C00060
Department of Health and Human Services
$214K
Mar 7, 2023

TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS.

NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2023
75N93019C00060
Department of Health and Human Services
$394K
Aug 22, 2022

TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS.

NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2022
75N93019C00060
Department of Health and Human Services
$499K
Jun 6, 2022

TO ADVANCE THE LEAD UNIVERSAL INFLUENZA VACCINE CANDIDATE THROUGH A PHASE I CLINICAL STUDY AND TO EVALUATE THE LONG-TERM IMMUNOGENICITY WITH ONE AND / OR TWO IMMUNIZATIONS.

NAICS: 541714 - RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)FY2022

Business Details

UEI
VSMPM3EGYYA6
CAGE Code
7TEE7
Address
110 CANAL ST FL 4
LOWELL, MA 018524574
Congressional District
MA-03

Parent Company

VERSATOPE THERAPEUTICS INC

Data Source

This profile is based on federal contract award data from USAspending.gov.

View on USAspending.gov